- Home
- GLTO vs RKDA Comparison
GLTO vs RKDA Comparison
Compare GLTO & RKDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLTO
- RKDA
- Stock Information
- Founded
- GLTO 2011
- RKDA 2002
- Country
- GLTO Denmark
- RKDA United States
- Employees
- GLTO N/A
- RKDA N/A
- Industry
- GLTO Biotechnology: Pharmaceutical Preparations
- RKDA Agricultural Chemicals
- Sector
- GLTO Health Care
- RKDA Industrials
- Exchange
- GLTO Nasdaq
- RKDA Nasdaq
- Market Cap
- GLTO 6.5M
- RKDA 6.6M
- IPO Year
- GLTO 2020
- RKDA 2015
- Fundamental
- Price
- GLTO $3.97
- RKDA $3.22
- Analyst Decision
- GLTO Buy
- RKDA Strong Buy
- Analyst Count
- GLTO 1
- RKDA 1
- Target Price
- GLTO $10.00
- RKDA $6.00
- AVG Volume (30 Days)
- GLTO 16.9K
- RKDA 5.0K
- Earning Date
- GLTO 04-28-2025
- RKDA 05-08-2025
- Dividend Yield
- GLTO N/A
- RKDA N/A
- EPS Growth
- GLTO N/A
- RKDA N/A
- EPS
- GLTO N/A
- RKDA N/A
- Revenue
- GLTO N/A
- RKDA $5,482,000.00
- Revenue This Year
- GLTO N/A
- RKDA $14.50
- Revenue Next Year
- GLTO N/A
- RKDA $30.00
- P/E Ratio
- GLTO N/A
- RKDA N/A
- Revenue Growth
- GLTO N/A
- RKDA 24.00
- 52 Week Low
- GLTO $3.76
- RKDA $1.85
- 52 Week High
- GLTO $21.05
- RKDA $10.31
- Technical
- Relative Strength Index (RSI)
- GLTO 36.86
- RKDA 25.61
- Support Level
- GLTO $3.76
- RKDA $3.20
- Resistance Level
- GLTO $4.21
- RKDA $3.39
- Average True Range (ATR)
- GLTO 0.27
- RKDA 0.21
- MACD
- GLTO -0.01
- RKDA -0.04
- Stochastic Oscillator
- GLTO 22.58
- RKDA 2.09
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.
About RKDA Arcadia Biosciences Inc.
Arcadia Biosciences Inc is a producer and marketer of plant-based food and beverage products. It is engaged in science-based approaches to developing high-value crop improvements in wheat, soy, and hemp, designed to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients, health, and wellness products, and their viability for industrial applications. The company's consumer brands in the food, beverage, and body care categories include GoodWheat high-fiber pasta, Zola coconut water and others.